围产期孕妇阴道分泌物B群链球菌感染和药物敏感性分析

目的了解围产期孕妇产前Ｂ群链球菌感染情况及药物敏感性，并通过分析为新生儿感染B群链球菌的防治提供依据。 方法收集宿迁市妇产医院，如皋妇产医院，如皋广慈医院等2019年1月到2020年3月份共4 750份妊娠35～37周孕妇阴道分泌物标本进行Ｂ群链球菌分离鉴定；阳性菌株用K-B法进行药敏试验。 结果4 750例阴道分泌物标本，检出B群链球菌225株，检出率为4.74%。药敏结果中，未检出对青霉素、万古霉素和利奈唑胺耐药的菌株，但青霉素敏感性下降，其抑菌圈在敏感折点上的占5.33%；氯霉素、左氧氟沙星、克林霉素、红霉素的耐药率分别为7.61%、57.94%、70.98%、80.44%；诱导克林霉素试验阳性率为9.43%。 结论B群链球菌在围产期妇女阴道分泌物检出率达4.74% ，β内酰胺类无耐药，但青霉素敏感度有下降表现。临床应重视围产期孕妇B群链球菌筛查，通过产前筛查和药物敏感试验有效的加以防治，做好预防性治疗，降低产妇及婴儿病患率。

Group B streptococcus infection and drug sensitivity analysis in vaginal secretions from perinatal pregnant women

ObjectiveTo understand the situation and drug sensitivity of antenatal group B streptococcus infection in perinatal pregnant women, and to provide basis for the prevention and treatment of group B streptococcus infection in neonates. MethodsFrom January 2019 to March 2020, a total of 4 750 samples of vaginal secretions from pregnant women at 35~37 weeks of gestation were collected from Suqian Maternity Hospital, Rugao Maternity Hospital and Rugao Guangci Hospital for the isolation and identification of group B streptococcus; The drug sensitivity test of the positive strain was carried out by K-B method. Results225 strains of group B streptococcus were detected in 4 750 samples of vaginal secretions, with a detection rate of 4.74%. Among the drug sensitivity results, no strains resistant to penicillin, vancomycin and linezolid were detected, but the sensitivity of penicillin decreased, and the inhibitory zone accounted for 5.33% at the sensitive fold point; The drug resistance rates of chloramphenicol, levofloxacin, clindamycin and erythromycin were 7.61%, 57.94%, 70.98% and 80.44% respectively. The positive rate of induction clindamycin test was 9.43%. ConclusionIn perinatal period, the infection rate of group B streptococcus vaginal secretions reached 4.74%, and lactams showed no resistance, but the sensitivity of penicillin showed a decline. Clinical attention should be paid to the screening of group B streptococcus in perinatal pregnant women, which should be effectively prevented through prenatal screening and drug sensitivity test, and preventive treatment should be done to reduce the rate of maternal and infant patients.